Myocardial beta adrenoceptor and voltage sensitive calcium channel changes in a canine model of chronic heart failure

P J Gengo1, H N Sabbah, R P Steffen

  • 1Division of Pharmacology, Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.

Insights

Chronic heart failure in dogs reduced beta adrenoceptors and calcium channels in the heart. This study investigated these changes in receptor binding and cardiac function.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Chronic heart failure (CHF) significantly alters cardiac function.
  • Understanding molecular changes in CHF is crucial for developing treatments.

Purpose of the Study:

  • To investigate the effects of chronic heart failure on receptor binding and cardiac function in a canine model.
  • To quantify changes in myocardial beta-adrenoceptors and voltage-sensitive calcium channels in heart failure.

Main Methods:

  • Heart failure was induced in mongrel dogs using sequential intracoronary microembolizations.
  • Myocardial beta-adrenoceptors and calcium channels were quantified using radioligand binding assays with [3H]dihydroalprenolol and [3H]nitrendipine.
  • Scatchard analysis was used to determine binding site density and affinity.

Main Results:

  • Heart failure was characterized by depressed cardiac function, hypertrophy, and dilation.
  • A significant decrease of 47% in [3H]dihydroalprenolol binding sites (beta-adrenoceptors) was observed.
  • A significant decrease of 20% in [3H]nitrendipine binding sites (calcium channels) was observed.
  • Binding affinities for both ligands remained unchanged.

Conclusions:

  • Chronic heart failure in this canine model is associated with a significant reduction in the density of myocardial beta-adrenoceptors and voltage-sensitive calcium channels.
  • These changes in receptor density may contribute to the altered cardiac function observed in heart failure.
  • Further research is needed to explore the therapeutic implications of these findings.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...